NCT05113745 - A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects with Narcolepsy (ENCORE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

September 12, 2024

Study Completion Date

November 15, 2024

Conditions

NarcolepsyCataplexyExcessive Daytime Sleepiness

Interventions

DRUG

AXS-12 (reboxetine)

AXS-12 tablets, taken twice daily

DRUG

Placebo

Placebo tablets, taken twice daily

Trial Locations (25)

19610

Clinical Research Site, Wyomissing

20815

Clinical Research Site, Chevy Chase

28037

Clinical Research Site, Denver

28054

Clinical Research Site, Gastonia

28078

Clinical Research Site, Huntersville

29201

Clinical Research Site, Columbia

29425

Clinical Research Site, Charleston

30281

Clinical Research Site, Stockbridge

30315

Clinical Research Site, Atlanta

30328

Clinical Research Site, Atlanta

32789

Clinical Research Site, Winter Park

33016

Clinical Research Site, Miami Lakes

33122

Clinical Research Site, Doral

33511

Clinical Research Site, Brandon

33765

Clinical Research Site, Clearwater

45245

Clinical Research Site, Cincinnati

48377

Clinical Research Site, Novi

49008

Clinical Research Site, Kalamazoo

78229

Clinical Research Site, San Antonio

78731

Clinical Research Site, Austin

80301

Clinical Research Site, Boulder

80918

Clinical Research Site, Colorado Springs

85054

Clinical Research Site, Phoenix

07753

Clinical Research Site, Neptune City

M5S 3A3

Clinical Research Site, Toronto